SODIUM PHENYLBUTYRATE

Information current as at: 1 April 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Pheburane®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Condition/indication:
(therapeutic use)
  • Urea cycle disorder (UCD)
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC submission type:
New listing (Minor)
Comment:
--
Submission sponsor:
Orpharma Pty Ltd
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2019 PBAC meeting
Opportunity for consumer comment:
Open 01/05/2019 and close 12/06/2019 (see PBS Website)
PBAC meeting:
Held on 10/07/2019
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
09/08/2019
Lodgement of required documentation:
19/08/2019
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 22/08/2019
Status:
Finalised
Government processes:
Commenced on 03/09/2019
Medicine listed on the PBS:
01/12/2019 (see PBS schedule)

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information

Case ID: a048

Page last updated: 31 March 2026

v.9.19